Tenaya Therapeutics, Inc. SEC filings TNYA
Tenaya Therapeutics, Inc. has 353 filings in SEC EDGAR's recent list, going back to May 7, 2021. Its latest annual report, Form ARS, was filed on Apr 16, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| DEFA14A | Additional proxy material | Oct 23, 2026 | — |
| DEF 14A | Proxy statement | Oct 23, 2026 | Dec 9, 2026 |
| PRE 14A | Preliminary proxy statement | Oct 13, 2026 | Dec 9, 2026 |
| S-8 | Employee stock plan registration | Aug 5, 2026 | — |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Agreement ended
|
Jul 2, 2026 | Jun 29, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jun 29, 2026 | Jun 29, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
May 29, 2026 | May 27, 2026 |
| 10-Q | Quarterly report | May 6, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 6, 2026 | May 6, 2026 |
| ARS | Annual report to shareholders | Apr 16, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 16, 2026 | — |
| DEF 14A | Proxy statement | Apr 16, 2026 | May 27, 2026 |
| 10-K | Annual report | Mar 11, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 11, 2026 | Mar 11, 2026 |
| 8-K |
Current report
Material agreement
|
Mar 5, 2026 | Mar 4, 2026 |
| S-8 | Employee stock plan registration | Feb 3, 2026 | — |
| 8-K |
Current report
Listing notice, Officer or director change
|
Jan 30, 2026 | Jan 26, 2026 |
| 8-K |
Current report
Officer or director change
|
Jan 2, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Dec 12, 2025 | Dec 11, 2025 |
| 424B5 | Prospectus supplement | Dec 12, 2025 | — |
| 424B5 | Prospectus supplement | Dec 11, 2025 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 11, 2025 | Dec 11, 2025 |
| 10-Q | Quarterly report | Nov 10, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 10, 2025 | Nov 10, 2025 |
| 8-K |
Current report
Other events
|
Nov 7, 2025 | Nov 7, 2025 |
| UPLOAD | Letter from the SEC | Sep 10, 2025 | — |
| CORRESP | Letter to the SEC | Sep 4, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 26, 2025 | — |
| 10-Q | Quarterly report | Aug 6, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2025 | Aug 6, 2025 |
| 8-K |
Current report
Shareholder vote results
|
May 30, 2025 | May 28, 2025 |
| 10-Q | Quarterly report | May 7, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
May 7, 2025 | May 7, 2025 |
| 8-K |
Current report
Listing notice
|
Apr 18, 2025 | Apr 15, 2025 |
| ARS | Annual report to shareholders | Apr 17, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 17, 2025 | — |
| DEF 14A | Proxy statement | Apr 17, 2025 | May 28, 2025 |
| EFFECT | Filing | Mar 31, 2025 | — |
| 8-K |
Current report
Exit or restructuring costs
|
Mar 28, 2025 | Mar 27, 2025 |
| CORRESP | Letter to the SEC | Mar 27, 2025 | — |
| UPLOAD | Letter from the SEC | Mar 26, 2025 | — |
| S-3 | Shelf registration | Mar 21, 2025 | — |
| 10-K | Annual report | Mar 10, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 10, 2025 | Mar 10, 2025 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure, Other events
|
Mar 4, 2025 | Mar 3, 2025 |
| 424B5 | Prospectus supplement | Mar 4, 2025 | — |
| 424B5 | Prospectus supplement | Mar 3, 2025 | — |
| 424B3 | Prospectus | Mar 3, 2025 | — |
| S-8 | Employee stock plan registration | Feb 7, 2025 | — |
| 8-K |
Current report
Officer or director change
|
Feb 7, 2025 | Feb 6, 2025 |
| 8-K |
Current report
Officer or director change
|
Jan 28, 2025 | Jan 24, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 17, 2024 | Dec 17, 2024 |
| 8-K |
Current report
Officer or director change
|
Dec 17, 2024 | Dec 16, 2024 |
| 10-Q | Quarterly report | Nov 6, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 6, 2024 | Nov 6, 2024 |
| S-8 | Employee stock plan registration | Sep 17, 2024 | — |
| 8-K |
Current report
Officer or director change
|
Sep 16, 2024 | Sep 12, 2024 |
| 10-Q | Quarterly report | Aug 8, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Results of operations, Officer or director change
|
Aug 8, 2024 | Aug 8, 2024 |
| 8-K |
Current report
Officer or director change
|
Jul 25, 2024 | Jul 19, 2024 |
| 8-K |
Current report
Officer or director change
|
Jun 27, 2024 | Jun 25, 2024 |
| 8-K |
Current report
Shareholder vote results
|
May 31, 2024 | May 30, 2024 |
| 10-Q | Quarterly report | May 14, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Results of operations, Exit or restructuring costs
|
May 14, 2024 | May 13, 2024 |
| ARS | Annual report to shareholders | Apr 17, 2024 | Dec 31, 2023 |
| DEFA14A | Additional proxy material | Apr 17, 2024 | — |
| DEF 14A | Proxy statement | Apr 17, 2024 | May 30, 2024 |
| 10-K | Annual report | Mar 18, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Results of operations
|
Mar 18, 2024 | Mar 18, 2024 |
| 424B5 | Prospectus supplement | Feb 8, 2024 | — |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Feb 8, 2024 | Feb 7, 2024 |
| S-8 | Employee stock plan registration | Jan 31, 2024 | — |
| 10-Q | Quarterly report | Nov 8, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 8, 2023 | Nov 8, 2023 |
| 10-Q | Quarterly report | Aug 9, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 9, 2023 | Aug 9, 2023 |
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change, Shareholder vote results
|
Jun 12, 2023 | Jun 8, 2023 |
| 10-Q | Quarterly report | May 10, 2023 | Mar 31, 2023 |
| 8-K |
Current report
Results of operations
|
May 10, 2023 | May 10, 2023 |
| ARS | Annual report to shareholders | Apr 27, 2023 | Dec 31, 2022 |
| DEFA14A | Additional proxy material | Apr 27, 2023 | — |
| DEF 14A | Proxy statement | Apr 27, 2023 | Jun 8, 2023 |
| PRE 14A | Preliminary proxy statement | Apr 17, 2023 | Jun 8, 2023 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Mar 21, 2023 | Mar 16, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 13, 2023 | Mar 10, 2023 |
| S-8 | Employee stock plan registration | Mar 8, 2023 | — |
| 10-K | Annual report | Mar 8, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Results of operations
|
Mar 8, 2023 | Mar 8, 2023 |
| 8-K |
Current report
Officer or director change
|
Dec 7, 2022 | Dec 5, 2022 |
| 8-K |
Current report
Material agreement, Other events
|
Nov 17, 2022 | Nov 16, 2022 |
| 424B5 | Prospectus supplement | Nov 17, 2022 | — |
| 424B5 | Prospectus supplement | Nov 16, 2022 | — |
| 10-Q | Quarterly report | Nov 10, 2022 | Sep 30, 2022 |
| 8-K |
Current report
Results of operations
|
Nov 10, 2022 | Nov 10, 2022 |
| EFFECT | Filing | Aug 17, 2022 | — |
| 424B5 | Prospectus supplement | Aug 17, 2022 | — |
| CORRESP | Letter to the SEC | Aug 15, 2022 | — |
| UPLOAD | Letter from the SEC | Aug 12, 2022 | — |
| 8-K |
Current report
Material agreement
|
Aug 10, 2022 | Aug 10, 2022 |
| S-3 | Shelf registration | Aug 10, 2022 | — |
| 10-Q | Quarterly report | Aug 10, 2022 | Jun 30, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2022 | Aug 10, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Jun 10, 2022 | Jun 9, 2022 |
| 10-Q | Quarterly report | May 11, 2022 | Mar 31, 2022 |
| 8-K |
Current report
Results of operations
|
May 11, 2022 | May 11, 2022 |
| DEFA14A | Additional proxy material | Apr 28, 2022 | — |
| DEF 14A | Proxy statement | Apr 28, 2022 | Jun 9, 2022 |
| S-8 | Employee stock plan registration | Mar 23, 2022 | — |
| 10-K | Annual report | Mar 23, 2022 | Dec 31, 2021 |
| 8-K |
Current report
Results of operations
|
Mar 23, 2022 | Mar 23, 2022 |
| 8-K |
Current report
Officer or director change
|
Dec 22, 2021 | Dec 22, 2021 |
| 8-K |
Current report
Officer or director change
|
Nov 22, 2021 | Nov 17, 2021 |
| 10-Q | Quarterly report | Nov 10, 2021 | Sep 30, 2021 |
| 8-K |
Current report
Results of operations
|
Nov 10, 2021 | Nov 10, 2021 |
| 10-Q | Quarterly report | Sep 8, 2021 | Jun 30, 2021 |
| 8-K |
Current report
Results of operations
|
Sep 8, 2021 | Sep 8, 2021 |
| 8-K |
Current report
Bylaw or fiscal year change, Regulation FD disclosure
|
Aug 3, 2021 | Aug 3, 2021 |
| SEC STAFF LETTER | Filing | Aug 2, 2021 | — |
| S-8 | Employee stock plan registration | Jul 30, 2021 | — |
| 424B4 | Prospectus | Jul 30, 2021 | — |
| EFFECT | Filing | Jul 29, 2021 | — |
| S-1MEF | Filing | Jul 29, 2021 | — |
| CERT | Filing | Jul 27, 2021 | — |
| CORRESP | Letter to the SEC | Jul 27, 2021 | — |
| CORRESP | Letter to the SEC | Jul 27, 2021 | — |
| CORRESP | Letter to the SEC | Jul 26, 2021 | — |
| S-1/A | Amended registration statement | Jul 26, 2021 | — |
| 8-A12B | Filing | Jul 23, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 15, 2021 | — |
| CORRESP | Letter to the SEC | Jul 9, 2021 | — |
| S-1 | Registration statement | Jul 9, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 24, 2021 | — |
| DRS/A | Filing | Jun 16, 2021 | — |
| DRSLTR | Filing | Jun 15, 2021 | — |
| SEC STAFF LETTER | Filing | Jun 10, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 3, 2021 | — |
| DRS | Filing | May 7, 2021 | — |
Showing 141 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- TNYA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1858848
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.